Abbott Laboratories (ABT)

$105.46 -1.66 (-1.55%)
Market Cap 185.36B
Revenue (ttm) 44.33B
Net Income (ttm) 6.52B
EPS (ttm) N/A
PE Ratio 20.10
Forward PE 19.15
Profit Margin 14.72%
Debt to Equity Ratio 0.63
Volume 8,157,000
Avg Vol 13,033,136
Day's Range N/A - N/A
Shares Out 1.73B
Stochastic %K 54%
Beta 0.59
Analysts Strong Sell
Price Target $119.65

Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement ther...

Industry: Medical Devices
Sector: Healthcare
Phone: 224 667 6100
Address:
100 Abbott Park Road, Abbott Park, United States
CharlesMikulak942
CharlesMikulak942 Aug. 5 at 6:39 AM
$BLK $ABT $NEE $UNP $TJX BlackRock remains the world's largest asset manager, Abbott Laboratories leads medical devices, NextEra Energy dominates renewable utilities, Union Pacific benefits from rail transportation demand, and TJX continues leading off-price retail.
0 · Reply
EZ_Money11
EZ_Money11 Aug. 4 at 10:44 PM
$ABT Gap below $90 🎯
0 · Reply
NasdaqFrontier6
NasdaqFrontier6 Aug. 2 at 10:07 PM
Q2 Earnings Winners So Far The biggest earnings reactions are showing one clear theme: Strong execution is still being rewarded. Healthcare & Medtech $BFLY +15.07% $CDNA +14.72% $GEHC +12.15% $ABT +10.71% $TMO +8.71% The takeaway: The market is rewarding companies with: • Real revenue growth • Strong margins • Clear demand trends • Positive guidance AI remains a major driver, but opportunities are expanding into cloud, infrastructure, industrials, and specialized technology. The next winners may come from the companies quietly building the future. Follow me and visit my profile for earnings breakdowns, AI infrastructure research, and high-conviction growth stock ideas before Wall Street fully prices them in.
1 · Reply
BioTechHealthX
BioTechHealthX Aug. 1 at 3:44 AM
$ABT Abbott Laboratories is expanding across diabetes technology, cancer diagnostics, medical devices and nutrition while raising its 2026 earnings outlook. Here is why ABT stock may be one of healthcare’s most dependable long-term opportunities. https://biotechhealthx.com/biotech-news/what-makes-abbott-abt-a-strong-choice-for-steady-growth/
0 · Reply
Logsen
Logsen Jul. 31 at 12:26 AM
$ABT strategy works. kingsignals.com
0 · Reply
healthcareguru
healthcareguru Jul. 30 at 10:37 PM
$MYGN I’m a Buyer down 40% here… Yes the qtr and guide were BAD. But this co is still doing near $800MN in sales and will open at ~0.4x fwd EV/sales…rock bottom valuation for a strategic asset that could help expand the footprint in community oncology for a larger Dx player. $ABT is a clear acquirer. Expect this to recover to down ~20-25% and be an M&A target after. HODL. 😬🦾 $XLV $IHI $XBI
0 · Reply
DBRGLong
DBRGLong Jul. 30 at 5:33 PM
$ABT RSI was in the mid 70's & getting overextended into overbought territory after this beautiful run for us. Not a bad thing for us to experience a little healthy consolidation at these levels. $110+ is on the way for us shortly, & in the coming weeks 🥂
0 · Reply
Orbit100
Orbit100 Jul. 30 at 3:11 PM
$ABT UBS Adjusts Price Target on Abbott Laboratories to $125 From $135, Maintains Buy Rating MT Newswires 10:17:22 AM ET, 07/28/2026
0 · Reply
Estimize
Estimize Jul. 30 at 2:57 PM
Wall St is expecting 1.42 EPS for $ABT Q3 [Reporting 10/21 BMO] http://www.estimize.com/intro/abt?chart=historical&metric_name=eps&utm_cont
0 · Reply
NRG8
NRG8 Jul. 29 at 7:12 PM
$TMUS $MS $PM $GS $ABT ....
0 · Reply
Latest News on ABT
3 ‘Strong Buy’ Dividend Aristocrat Stocks to Power Your Cash Flow, 7/30/26

2026-07-30T19:04:37.000Z - 5 days ago

3 ‘Strong Buy’ Dividend Aristocrat Stocks to Power Your Cash Flow, 7/30/26

CHRW LIN

Abbott price target lowered to $125 from $135 at UBS

2026-07-28T12:16:43.000Z - 7 days ago

Abbott price target lowered to $125 from $135 at UBS

FDA Approves Freenome's SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.

Jul 27, 2026, 8:00 AM EDT - 8 days ago

FDA Approves Freenome's SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.

FRNM

Abbott defeats shareholder lawsuit over 2022 infant formula recall

Jul 24, 2026, 4:07 PM EDT - 11 days ago

Abbott defeats shareholder lawsuit over 2022 infant formula recall

Abbott investigates two separate cyber incidents, says no operations affected

Jul 17, 2026, 7:02 PM EDT - 18 days ago

Abbott investigates two separate cyber incidents, says no operations affected

Abbott price target raised to $115 from $102 at BofA

2026-07-17T13:25:13.000Z - 18 days ago

Abbott price target raised to $115 from $102 at BofA

Abbott price target raised to $120 from $110 at JPMorgan

2026-07-17T11:25:38.000Z - 18 days ago

Abbott price target raised to $120 from $110 at JPMorgan

Abbott price target raised to $118 from $115 at Piper Sandler

2026-07-17T11:10:30.000Z - 18 days ago

Abbott price target raised to $118 from $115 at Piper Sandler

Abbott price target raised to $112 from $108 at Citi

2026-07-17T10:35:26.000Z - 18 days ago

Abbott price target raised to $112 from $108 at Citi

Abbott’s Q2 gives confidence in improving results, says William Blair

2026-07-16T19:35:12.000Z - 19 days ago

Abbott’s Q2 gives confidence in improving results, says William Blair

Abbott Laboratories Stock (ABT) Rallies on a Q2 Earnings Beat and a 2026 EPS Guidance Increase

2026-07-16T16:33:18.000Z - 19 days ago

Abbott Laboratories Stock (ABT) Rallies on a Q2 Earnings Beat and a 2026 EPS Guidance Increase

Abbott rises 10.7%

2026-07-16T16:05:18.000Z - 19 days ago

Abbott rises 10.7%

Abbott rises 12.5%

2026-07-16T14:06:30.000Z - 19 days ago

Abbott rises 12.5%

Abbott Laboratories Earnings Call Transcript: Q2 2026

Jul 16, 2026, 9:00 AM EDT - 19 days ago

Abbott Laboratories Earnings Call Transcript: Q2 2026

Abbott Laboratories Earnings release: Q2 2026

Jul 16, 2026, 9:00 AM EDT - 19 days ago

Abbott Laboratories Earnings release: Q2 2026

Abbott Laboratories Slides: Q2 2026

Jul 16, 2026, 9:00 AM EDT - 19 days ago

Abbott Laboratories Slides: Q2 2026

Abbott Laboratories Quarterly report: Q2 2026

Jul 16, 2026, 9:00 AM EDT - 19 days ago

Abbott Laboratories Quarterly report: Q2 2026

Abbott Laboratories Sales Rise on Diagnostics Growth

Jul 16, 2026, 8:08 AM EDT - 19 days ago

Abbott Laboratories Sales Rise on Diagnostics Growth

Abbott raises 2026 profit forecast on heart device strength

Jul 16, 2026, 7:33 AM EDT - 19 days ago

Abbott raises 2026 profit forecast on heart device strength

Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance

Jul 16, 2026, 7:30 AM EDT - 19 days ago

Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance

Value stocks beat growth when inflation is high. Here are 13 stocks top newsletters are betting on now.

Jun 29, 2026, 4:43 PM EDT - 5 weeks ago

Value stocks beat growth when inflation is high. Here are 13 stocks top newsletters are betting on now.

ADM APD BAC CMCSA CVS DIS FITB

US DOJ closes criminal probe into Abbott over baby formula plant, WSJ reports

Jun 28, 2026, 9:17 PM EDT - 5 weeks ago

US DOJ closes criminal probe into Abbott over baby formula plant, WSJ reports

The Baby Formula Probe Produced a Pile of Evidence. Then the DOJ Dropped the Case.

Jun 28, 2026, 9:00 PM EDT - 5 weeks ago

The Baby Formula Probe Produced a Pile of Evidence. Then the DOJ Dropped the Case.

Abbott hosts conference call for second-quarter earnings

Jun 25, 2026, 9:00 AM EDT - 5 weeks ago

Abbott hosts conference call for second-quarter earnings

ALZpath Signs Global Licensing Agreement with Abbott to Advance Blood-Based Alzheimer's Disease Testing

Jun 24, 2026, 8:30 AM EDT - 5 weeks ago

ALZpath Signs Global Licensing Agreement with Abbott to Advance Blood-Based Alzheimer's Disease Testing

ALZpath signs licensing deal with Abbott to develop Alzheimer's blood test

Jun 24, 2026, 7:36 AM EDT - 5 weeks ago

ALZpath signs licensing deal with Abbott to develop Alzheimer's blood test

Missouri appeals court won't send Abbott's appeal of $495 million preterm baby formula verdict to higher court

Jun 23, 2026, 1:34 PM EDT - 6 weeks ago

Missouri appeals court won't send Abbott's appeal of $495 million preterm baby formula verdict to higher court

New Similac® survey finds social media pressure to be "perfect" is fueling a shift toward authenticity for the next generation of parents

Jun 22, 2026, 12:00 PM EDT - 6 weeks ago

New Similac® survey finds social media pressure to be "perfect" is fueling a shift toward authenticity for the next generation of parents

Living Longer Is Big Business. These Stocks Will Benefit.

Jun 18, 2026, 2:14 PM EDT - 6 weeks ago

Living Longer Is Big Business. These Stocks Will Benefit.

DXCM GH HIMS PLNT

The Healthcare M&A Wave

Jun 17, 2026, 12:30 PM EDT - 6 weeks ago

The Healthcare M&A Wave

ALNY AMGN AMRX ANTX AZN BDX BEAM

Abbott declares 410th consecutive quarterly dividend

Jun 12, 2026, 2:29 PM EDT - 7 weeks ago

Abbott declares 410th consecutive quarterly dividend

New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers

Jun 8, 2026, 9:00 AM EDT - 2 months ago

New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers

The U.S. stock market is facing historic downside risk — these 10 low-volatility stocks can protect your portfolio

Jun 6, 2026, 10:01 AM EDT - 2 months ago

The U.S. stock market is facing historic downside risk — these 10 low-volatility stocks can protect your portfolio

GIS KMB MDT O PPL ROP SNA

New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis

Jun 6, 2026, 9:00 AM EDT - 2 months ago

New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis

Abbott Labs must face lawsuit over PediaSure children's growth claims

Jun 4, 2026, 3:46 PM EDT - 2 months ago

Abbott Labs must face lawsuit over PediaSure children's growth claims

Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes

May 27, 2026, 9:00 AM EDT - 2 months ago

Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes

ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening

May 27, 2026, 7:01 AM EDT - 2 months ago

ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening

Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026

May 26, 2026, 9:00 AM EDT - 2 months ago

Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026

Even a High-Priced Market Has Bargains. 10 Undervalued Blue-Chip Stocks.

May 15, 2026, 1:00 AM EDT - 2 months ago

Even a High-Priced Market Has Bargains. 10 Undervalued Blue-Chip Stocks.

ACN DHR HD MCD MDT MKC RSG

Abbott receives FDA clearance and CE Mark for next-generation Ultreon™ 3.0 AI-powered coronary imaging platform

Apr 28, 2026, 9:00 AM EDT - 3 months ago

Abbott receives FDA clearance and CE Mark for next-generation Ultreon™ 3.0 AI-powered coronary imaging platform

Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026

Apr 25, 2026, 12:30 PM EDT - 3 months ago

Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026

New data at AACR 2026 demonstrate advancements in Cancerguard® Multi-Cancer Early Detection Test

Apr 17, 2026, 3:30 PM EDT - 3 months ago

New data at AACR 2026 demonstrate advancements in Cancerguard® Multi-Cancer Early Detection Test

Abbott Laboratories Cuts Outlook, Says Mild Flu Season Hurt Sales

Apr 16, 2026, 11:22 AM EDT - 3 months ago

Abbott Laboratories Cuts Outlook, Says Mild Flu Season Hurt Sales

Abbott Laboratories Earnings Call Transcript: Q1 2026

Apr 16, 2026, 9:00 AM EDT - 3 months ago

Abbott Laboratories Earnings Call Transcript: Q1 2026

Abbott Laboratories Earnings release: Q1 2026

Apr 16, 2026, 9:00 AM EDT - 3 months ago

Abbott Laboratories Earnings release: Q1 2026

Abbott Laboratories Slides: Q1 2026

Apr 16, 2026, 9:00 AM EDT - 3 months ago

Abbott Laboratories Slides: Q1 2026

Abbott Laboratories Quarterly report: Q1 2026

Apr 16, 2026, 9:00 AM EDT - 3 months ago

Abbott Laboratories Quarterly report: Q1 2026

Abbott Stock Tumbles on Earnings. Nutrition Business Is Struggling and Merger Costs Are Biting.

Apr 16, 2026, 8:05 AM EDT - 3 months ago

Abbott Stock Tumbles on Earnings. Nutrition Business Is Struggling and Merger Costs Are Biting.

Abbott first-quarter results beat on cancer diagnostics, medical device strength

Apr 16, 2026, 7:33 AM EDT - 3 months ago

Abbott first-quarter results beat on cancer diagnostics, medical device strength

Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences

Apr 16, 2026, 7:30 AM EDT - 3 months ago

Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences

Jury orders Abbott to pay $53 million in preterm infant formula trial, media report says

Apr 9, 2026, 10:16 PM EDT - 4 months ago

Jury orders Abbott to pay $53 million in preterm infant formula trial, media report says

New survey finds most Americans believe chronic diseases are preventable, but only 1 in 4 feel confident in how to care for their health

Apr 9, 2026, 9:00 AM EDT - 4 months ago

New survey finds most Americans believe chronic diseases are preventable, but only 1 in 4 feel confident in how to care for their health

Abbott expands access to Precision Oncology portfolio through integration with Flatiron's OncoEMR® platform

Mar 30, 2026, 9:00 AM EDT - 4 months ago

Abbott expands access to Precision Oncology portfolio through integration with Flatiron's OncoEMR® platform

Abbott hosts conference call for first-quarter earnings

Mar 26, 2026, 9:00 AM EDT - 4 months ago

Abbott hosts conference call for first-quarter earnings

John Stamos and Jodie Sweetin reunite for "The (Second) Talk" with Cologuard® tests, encouraging colon cancer screening

Mar 24, 2026, 8:00 AM EDT - 4 months ago

John Stamos and Jodie Sweetin reunite for "The (Second) Talk" with Cologuard® tests, encouraging colon cancer screening

Abbott completes acquisition of Exact Sciences

Mar 23, 2026, 8:50 AM EDT - 4 months ago

Abbott completes acquisition of Exact Sciences

Abbott acquisition of Exact Sciences set to close on March 23, 2026

Mar 20, 2026, 9:00 AM EDT - 4 months ago

Abbott acquisition of Exact Sciences set to close on March 23, 2026

Pivot Bio CEO Chris Abbott to Present at World Agri-Tech Innovation Summit

Mar 13, 2026, 2:17 PM EDT - 5 months ago

Pivot Bio CEO Chris Abbott to Present at World Agri-Tech Innovation Summit

Abbott Laboratories Proxy statement: Proxy Filing

Mar 13, 2026, 8:00 AM EDT - 5 months ago

Abbott Laboratories Proxy statement: Proxy Filing

Abbott Laboratories Proxy statement: Proxy Filing

Mar 13, 2026, 8:00 AM EDT - 5 months ago

Abbott Laboratories Proxy statement: Proxy Filing

Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management

Mar 12, 2026, 8:00 AM EDT - 5 months ago

Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management

Exact Sciences Stockholders Approve Acquisition by Abbott

Feb 20, 2026, 4:05 PM EST - 5 months ago

Exact Sciences Stockholders Approve Acquisition by Abbott

EXAS

Abbott declares 409th consecutive quarterly dividend

Feb 20, 2026, 11:38 AM EST - 5 months ago

Abbott declares 409th consecutive quarterly dividend

Carl Abbott's “House of Columns” Brings Sarasota School Modernism to the Market on Longboat Key

Feb 17, 2026, 11:32 AM EST - 6 months ago

Carl Abbott's “House of Columns” Brings Sarasota School Modernism to the Market on Longboat Key

These 32 favorite stocks signal the bull market is running on fumes

Feb 12, 2026, 8:05 AM EST - 6 months ago

These 32 favorite stocks signal the bull market is running on fumes

AAPL ADBE AMGN AVGO BAC BMY COF

Late-breaking data presentations showcase the safety and efficacy of Abbott's ablation catheters to treat people with atrial fibrillation

Feb 6, 2026, 8:00 AM EST - 6 months ago

Late-breaking data presentations showcase the safety and efficacy of Abbott's ablation catheters to treat people with atrial fibrillation

Abbott recalls glucose sensors after seven deaths linked to faulty readings

Feb 4, 2026, 10:49 AM EST - 6 months ago

Abbott recalls glucose sensors after seven deaths linked to faulty readings

Is The Fall In Abbott Stock Justified?

Jan 23, 2026, 9:35 AM EST - 6 months ago

Is The Fall In Abbott Stock Justified?

Abbott faces India scrutiny in cough syrup abuse investigation, documents show

Jan 23, 2026, 6:43 AM EST - 6 months ago

Abbott faces India scrutiny in cough syrup abuse investigation, documents show

Abbott Laboratories Raised Prices, Prompting Sales Slump

Jan 22, 2026, 2:31 PM EST - 6 months ago

Abbott Laboratories Raised Prices, Prompting Sales Slump

CharlesMikulak942
CharlesMikulak942 Aug. 5 at 6:39 AM
$BLK $ABT $NEE $UNP $TJX BlackRock remains the world's largest asset manager, Abbott Laboratories leads medical devices, NextEra Energy dominates renewable utilities, Union Pacific benefits from rail transportation demand, and TJX continues leading off-price retail.
0 · Reply
EZ_Money11
EZ_Money11 Aug. 4 at 10:44 PM
$ABT Gap below $90 🎯
0 · Reply
NasdaqFrontier6
NasdaqFrontier6 Aug. 2 at 10:07 PM
Q2 Earnings Winners So Far The biggest earnings reactions are showing one clear theme: Strong execution is still being rewarded. Healthcare & Medtech $BFLY +15.07% $CDNA +14.72% $GEHC +12.15% $ABT +10.71% $TMO +8.71% The takeaway: The market is rewarding companies with: • Real revenue growth • Strong margins • Clear demand trends • Positive guidance AI remains a major driver, but opportunities are expanding into cloud, infrastructure, industrials, and specialized technology. The next winners may come from the companies quietly building the future. Follow me and visit my profile for earnings breakdowns, AI infrastructure research, and high-conviction growth stock ideas before Wall Street fully prices them in.
1 · Reply
BioTechHealthX
BioTechHealthX Aug. 1 at 3:44 AM
$ABT Abbott Laboratories is expanding across diabetes technology, cancer diagnostics, medical devices and nutrition while raising its 2026 earnings outlook. Here is why ABT stock may be one of healthcare’s most dependable long-term opportunities. https://biotechhealthx.com/biotech-news/what-makes-abbott-abt-a-strong-choice-for-steady-growth/
0 · Reply
Logsen
Logsen Jul. 31 at 12:26 AM
$ABT strategy works. kingsignals.com
0 · Reply
healthcareguru
healthcareguru Jul. 30 at 10:37 PM
$MYGN I’m a Buyer down 40% here… Yes the qtr and guide were BAD. But this co is still doing near $800MN in sales and will open at ~0.4x fwd EV/sales…rock bottom valuation for a strategic asset that could help expand the footprint in community oncology for a larger Dx player. $ABT is a clear acquirer. Expect this to recover to down ~20-25% and be an M&A target after. HODL. 😬🦾 $XLV $IHI $XBI
0 · Reply
DBRGLong
DBRGLong Jul. 30 at 5:33 PM
$ABT RSI was in the mid 70's & getting overextended into overbought territory after this beautiful run for us. Not a bad thing for us to experience a little healthy consolidation at these levels. $110+ is on the way for us shortly, & in the coming weeks 🥂
0 · Reply
Orbit100
Orbit100 Jul. 30 at 3:11 PM
$ABT UBS Adjusts Price Target on Abbott Laboratories to $125 From $135, Maintains Buy Rating MT Newswires 10:17:22 AM ET, 07/28/2026
0 · Reply
Estimize
Estimize Jul. 30 at 2:57 PM
Wall St is expecting 1.42 EPS for $ABT Q3 [Reporting 10/21 BMO] http://www.estimize.com/intro/abt?chart=historical&metric_name=eps&utm_cont
0 · Reply
NRG8
NRG8 Jul. 29 at 7:12 PM
$TMUS $MS $PM $GS $ABT ....
0 · Reply
1212JM
1212JM Jul. 29 at 3:53 PM
$ABT potential cup and handle forming on 6 month chart. Need to rally to 118-120 (to fully form the cup) and then pullback to 112-115 (to fully form the handle) to confirm.
0 · Reply
TalkMarkets
TalkMarkets Jul. 29 at 6:53 AM
These 3 Companies Reported Record Results And Raised Guidance $ABT $TSM $JNJ https://talkmarkets.com/article/these-3-companies-reported-record-results-and-raised-guidance-1785307979
0 · Reply
abubnic
abubnic Jul. 28 at 7:11 PM
Global CGM Revenue: ~33.8% to 34% controlled by $DXCM, trailing $ABT FreeStyle Libre (~52%), with $MDT holding the remainder. $DXCM U.S. Market Share: ~74% of the domestic CGM sector, reflecting strong domestic adoption and insurance coverage.
0 · Reply
Enjoy_Life_Bro
Enjoy_Life_Bro Jul. 28 at 2:18 PM
$ABT 👍👍
0 · Reply
1212JM
1212JM Jul. 28 at 1:55 PM
$ABT key resistance levels: $106.50: big break throu this one already today. $109.23 is next, $111.96 is next, $125.75 is next.
0 · Reply
BossBishhh28
BossBishhh28 Jul. 28 at 1:54 PM
$ABT helllllllz yeah
0 · Reply
1212JM
1212JM Jul. 28 at 1:33 PM
$ABT $120
0 · Reply
oestelle
oestelle Jul. 28 at 12:40 PM
$ABT can’t be greedy. Taking profits and rotating into $CRDO. One winner funds the next. 🚀
2 · Reply
saab93boi
saab93boi Jul. 28 at 3:13 AM
$ABT Decided to close my lot of shares here at 104.80 today and rotate into $CMCSA at 22.90. Comcast is still a money machine, holds valuable assets, and working on buybacks. That 5% dividend is great while i wait for recovery.
0 · Reply
iBoughtTheWrongTicker
iBoughtTheWrongTicker Jul. 27 at 5:52 PM
$ABT and then some. $110 imminent
0 · Reply
BioTechHealthX
BioTechHealthX Jul. 26 at 12:08 PM
$ABT $NVO $NVS $PFE $UNH Explore 10 of the best medicine stocks positioned to benefit from rising demand for obesity treatments, oncology drugs, diabetes care, diagnostics and innovative healthcare technology. https://biotechhealthx.com/biotech-news/10-best-medicine-stocks-that-could-make-investors-100-richer/
0 · Reply
lousybiotechinvestor
lousybiotechinvestor Jul. 25 at 11:58 AM
When does $ABT finally buyout $SENS ?
0 · Reply